AbbVie Inc. (ABBV) has seen its price targets raised by both Citi and UBS to $260, a 13% increase from the previous target of $230. However, both firms maintain a Neutral rating on the stock, signaling caution despite the optimism in valuations.
Brokerage Recommendations and Valuation Insights
The average brokerage recommendation for AbbVie stands at 1.61, which is between Strong Buy and Buy, based on assessments from 32 firms. Out of these, 21 have issued Strong Buy ratings, suggesting strong potential. Nonetheless, Zacks has assigned a Rank #4 (Sell) to ABBV, indicating a bearish sentiment. The consensus estimate for this year's earnings per share (EPS) has decreased by 0.6% to $14.23, reflecting a trend of lowering earnings estimates.
In terms of valuation, GuruFocus identifies AbbVie as approximately 16.4% overvalued, with a current P/E ratio of 121.77x, significantly higher than its five-year median of 47.36x. This valuation concern may impact investor sentiment moving forward.
Insider Activity and Earnings Expectations
Despite the mixed signals from analysts, insider trading activity has been notably quiet, with no buying or selling reported in the past three months. This indicates that insiders are not actively trading their shares, which may reflect their confidence in the company's future performance.
AbbVie is expected to report its Q2 earnings soon, and both Citi and UBS analysts express a cautiously optimistic outlook for these results. Currently, ABBV is trading around $247.19, with the stock showing a slight increase of about 1% on the day.
This material is informational and not financial advice.
